


Supplementary Figure 1. MicroRNA expression in HF patients receiving carvedilol (Treated) compared with non-HF (Healthy) individuals.

Dot plots show fold-change of expression of miR-1, miR-133, miR-208 and miR-214 in HF patients receiving carvedilol (Treated) compared with non-HF (Healthy) individuals.


ns: no significant difference (P>0.05) between miRNA expressions in HF patients receiving carvedilol (Treated) compared with non-HF (Healthy) group.



Supplementary Figure 2. MicroRNA expression in HF patients not receiving carvedilol (Untreated) compared with non-HF (Healthy) individuals.

Dot plots show fold-change of expression of miR-1, miR-133, miR-208 and miR-214 in HF patients not receiving carvedilol (Untreated) compared with non-HF (Healthy) individuals.

\*: significant difference (P<0.05) and ns: no significant difference (P>0.05) between miRNA expressions in HF patients not treated with carvedilol (Untreated) and non-HF (Healthy) group.



Supplementary Figure 3. MicroRNA expression in HF patients treated with carvedilol (Treated) and HF patients not treated with carvedilol (Untreated).

Dot plots show fold-change of expression of miR-1, miR-133, miR-208 and miR-214 in HF patients treated with carvedilol (Treated) and untreated HF group (Untreated).

\*: significant difference (P<0.05) and ns: no significant difference (P>0.05) between miRNA expressions in HF patients treated with carvedilol (Treated) and untreated HF group (Untreated).